| Home | E-Submission | Sitemap | Contact Us |  
J Korean Cancer Assoc > Volume 27(1); 1995 > Article
Journal of the Korean Cancer Association 1995;27(1): 92-101.
비호지킨림프종에 대한 VACOP-B ( VP-16 , doxorubicin , cyclophosphamide , vincristine , prednisone , and bleomycin ) 복합화학요법
길준영, 최지영, 윤환중, 전의건, 조덕연, 김삼용
VACOP-B ( VP-16 , doxorubicin , cyclophosphamide , vincristine , prednisone , and bleomycin ) Chemotherapy for Non - Hodgkin's Lymphoma
Jun Young Kil, Jee Young Choi, Hwan Jung Yun, Eui Gun Chun, Deog Yeon Jo, Sam Yong Kim
Background: VACOP-B(VP-16, doxorubicin, vincristine, prednisone, and bleomycin), a regi- men emphasizing weekly treatment and brief duration (12weeks), has been reported to be ef- fective for the treatment of aggressive non-Hodgkin's lymphoma. We assessed the efficacy and the toxicity of VACOP-B treatment on an outpatient basis in patients with non-Hodgkin's lym- phoma. Patients and
Between August 1990 and August 1994, 25 patients with non-Hodgkin's lymphoma were treated with VACOP-B regimen on an outpatient basis. 23 of the 25 patients (92%)had intermediate-or high-grade lymphomas. Of the 23 evaluable patients, six received prior chemotherapy or radiation therapy.
Among the 23 evaluable patients, 19(76%) achieved a complete response and three (12%) achieved partial respones. With a medinan follow-up of 24 months, survival ranged 2~44 + months. The acturial 3 year survival was 54%. Out of the 25 patients, eight (32%) experienced a marked leukopenia (<1,000/mm(3)), of whom seven rmuired hospitalization due to infection. Non-hematologic toxicities were mild; grade I or II toxicities were noticed (mucositis 36%: peripheral neuropathy 68%). Two died of the toxicity related to the chemotherapy(infection1 Lower stage, complete response rather than partial response were associated with a longer survivaL
These results indicate that VACOP-B is effective, well tolerated, and feasible on an outpatient basis in the treatment of non-HodRkin's lymphoma. The use of hemopoietic growth factors such as granulocyte-colony stimulating factor or granulocyte-macrophage-colo- ny stimulating factor might circumvent the leukopenia and facilitate delivery of chemotherapy at full doses.
Key words: Non-Hodgkin's lymphoma, VACOP-B chemotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI